Table 1.
Baseline characteristics in participants with MSS mCRC
| Characteristics, n (%) | Favezelimab N = 20 |
Favezelimab + pembrolizumab N = 80 |
|---|---|---|
| Age, years, median (range) | 61.5 (36–80) | 58.0 (32–81) |
| >65 years, n (%) | 6 (30.0) | 19 (23.8) |
| Male, n (%) | 9 (45.0) | 54 (67.5) |
| ECOG PSa 1 | 14 (70.0) | 49 (61.3) |
| PD-L1 CPS ≥1 | 12 (60.0) | 36 (45.0) |
| PD-L1 CPS <1 | 8 (40.0) | 35 (43.8) |
| PD-L1 missing | 0 | 9 (11.2) |
| Prior lines of therapy, n (%) | ||
| Adjuvant | 0 | 2 (2.5) |
| 1 | 0 | 4 (5.0) |
| 2 | 3 (15.0) | 16 (20.0) |
| ≥3 | 17 (85.0) | 58 (72.5) |
CPS, combined positive score; mCRC, metastatic colorectal cancer; MSS, microsatellite stable; PD-L1, programmed death-ligand 1.
a
ECOG PS, Eastern Cooperative Oncology Group performance status.